Breo Ellipta (fluticasone furoate and vilanterol inhalation powder)

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder), for oral inhalation is a prescription medicine used to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both. Breo Ellipta is a maintenance therapy, and is not used to relieve sudden breathing problems and won’t replace a rescue inhaler.

What are the ingredients in Breo Ellipta?

The active ingredients in Breo Ellipta are fluticasone furoate and vilanterol trifenatate.

How does Breo Ellipta work?

Vilanterol is a long-acting beta2-adrenergic agonist (LABA). LABAs help to ensure that the muscles surrounding the airways are relaxed. This is important, because if those muscles become too tight then the airways can become too narrowed, making it difficult to breathe, causing COPD symptoms such as breathlessness, wheezing, and cough.

Fluticasone furoate is a an inhaled corticosteroid (ICS). Corticosteroids work by reducing inflammation and swelling and increasing airflow in the airways.

What are the possible side effects of Breo Ellipta?

In clinical trials of people with COPD, the most common adverse reactions were nasopharyngitis, upper respiratory tract infection, headache, thrush (oral candidiasis), back pain, pneumonia, bronchitis, sinusitis, cough, oropharyngeal pain, joint pain, hypertension, influenza, pharyngitis, and fever. This is not an exhaustive list of all potential side effects of Breo Ellipta. Talk to your healthcare provider or pharmacist for further information.

Things to know about Breo Ellipta

LABA medicines such as vilanterol (an active ingredient of Breo Ellipta) when used alone increase the risk of hospitalizations and death from asthma problems. Breo Ellipta contains an ICS and a LABA which, when used together, there is not a significant increased risk in hospitalizations and death from asthma problems.

Breo Ellipta should not be used:

  • To relieve sudden breathing problems. Always have a rescue inhaler with you to treat sudden symptoms.
  • In children and adolescents.
  • If you have a severe allergy to milk proteins or are allergic to any of the ingredients in BREO. Ask your healthcare provider if you are not sure.
  • With other medications that contain a LABA for any reason.

Do not use BREO more often than prescribed. Tell your healthcare provider about all the medicines you take and about all of your health conditions.

Seek medical attention if your breathing problems get worse, if you need your rescue inhaler more often than usual or it does not work as well to relieve your symptoms, or if your peak flow meter results decrease.

Dosing information

Breo Ellipta should be taken as 1 oral inhalation once daily, and should be used at the same time every day. Breo Ellipta should not be used more than 1 time every 24 hours. To reduce the risk of thrush, after inhalation, rinse your mouth with water without swallowing. Taking Breo Ellipta more than 1 inhalation daily is not recommended as some patients are more likely to experience adverse effects with higher doses. People using Breo Ellipta should not use additional LABA for any reason.

For more information, read the full prescribing information of Breo Ellipta.

Written by: Kristine Zerkowski | Last reviewed: April 2018.
View References
  1. Breo Ellipta [Prescribing Information]. Research Triangle Park: GlaxoSmithKline; December 2017.